Jump to any asset
As of September 9, 2026, Agilent Technologies Inc. (A) trades at $144.75. CleaRank Financial AI rates it Buy with a fair value of $177.50, 22.6% above the current price. Wall Street's consensus target is $177.50 across 22 analysts. RSI at 33 is in neutral territory, and the price is above its 50-day average of $142.78.
Agilent Technologies, Inc. (A)
Agilent Technologies, Inc. NYSE
$144.75
-2.100 (-1.43%)
At close: Sep 9, 4:00 PM EDT
AI Analyst Consensus
73 / 100
Agilent Technologies (A) is trading at $144.75, above its 50-day and 200-day moving averages ($142.78 and $131.61), with a bearish RSI momentum. Despite this, Wall Street maintains a strong 'Buy' consensus, supported by a median price target of $177.50, implying a 22.6% upside. The company's recent earnings have shown consistent beats on EPS estimates, with the latest quarter exceeding expectations by 8.72%. Revenue growth has been steady, projected at 8.1% for the current year and 6.0% for the next. The stock's current valuation, with a P/E ratio of 28.96, appears reasonable within the Healthcare Diagnostics & Research sector, especially considering its consistent performance and analyst optimism.
A Price Analysis
Market Metrics
Open
$145.23
Day Range
$143.75 to $146.40
Prev Close
$146.85
Volume
1.84M
52-Week Range
$108.35 to $163.75
Market Cap
$40.81B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (0.0155% difference), suggesting fair market pricing relative to industry standards.
A Analysis
Company's Health
4/5
12-Month Analyst Target
+22.63% Upside
Median of 22 analysts (12-month)
$177.50
AI Technical Analysis
Agilent Technologies (A) is currently trading below its 20-day EMA at $149.63, indicating short-term weakness, and its RSI is in bearish territory at 32.83. The stock is trading above its 50-day SMA of $142.78 and its 200-day SMA of $131.61, suggesting that longer-term support levels remain intact. Volume has been below average recently, with the latest volume at 1.84 million compared to a 2.55 million average. Key support is seen around the 50-day SMA, while resistance may form near the 20-day EMA. The current technical setup suggests a potential for a near-term pullback before a possible recovery, contingent on broader market sentiment and company-specific news.
ProTips
- Consider the current bearish technical momentum (RSI 32.83) as a potential entry point for long-term investors, given the strong analyst 'Buy' consensus and positive earnings trend.
- Monitor upcoming earnings reports closely; consistent beats have historically driven positive price action for Agilent Technologies (A).
- Given the moderate insider selling, it is prudent to focus on fundamental strength and analyst targets rather than insider activity as the primary investment driver.
Key Catalysts
Bullish
Consistent EPS Beats Drive Positive Sentiment
Agilent Technologies (A) has a strong history of exceeding analyst EPS estimates, with the latest quarter showing an 8.72% surprise. This trend supports a positive outlook and potential for stock price appreciation.
Source: Earnings ReportsBullish
Strong Analyst Conviction and Price Targets
With 22 analysts covering the stock, the consensus is predominantly 'Buy', and the median price target of $177.50 suggests a 22.6% upside from current levels.
Source: Wall Street AnalystsBearish
Moderate Insider Selling Activity
Insiders have sold $4.2 million worth of stock with no reported purchases, indicating a net selling trend. This 'Moderate Sell Signal' warrants monitoring for any acceleration.
Source: Insider TransactionsNeutral
Steady Revenue Growth Projections
Projected revenue growth of 8.1% for the current year and 6.0% for the next provides a stable foundation, though not explosive growth, for the company's valuation.
Source: Revenue EstimatesMarket Outlook
Agilent Technologies (A) is expected to maintain its positive trajectory over the next 6-12 months, driven by continued revenue growth and strong analyst support. The median price target of $177.50 suggests a base case scenario where the stock could appreciate by over 22% from its current price. Potential catalysts include further innovation in its diagnostic and research segments, successful integration of any new product launches, and continued positive earnings surprises. Downside risks could emerge from increased competition, unexpected regulatory changes in the healthcare sector, or a broader market downturn that impacts growth stocks.
Key Statistics
| Market Cap | 40.81B |
|---|---|
| P/E Ratio | 28.96 |
| EPS (TTM) | 5.07 |
| Dividend Yield | 0.6997% |
| 52 Week High | 163.75 |
| 52 Week Low | 108.35 |
Agilent Technologies (A) trades at a P/E ratio of 28.96, which aligns with its sector average for Healthcare Diagnostics & Research. The company has demonstrated consistent revenue growth, with an 8.1% increase reported for the current year and an estimated 6.0% for the next. Profitability is solid, as indicated by a positive EPS of $5.07. The balance sheet appears healthy. The company's ability to consistently beat earnings estimates suggests strong operational execution and a strong business model, supporting its current valuation and analyst price targets.
Earnings & Growth Analysis
Agilent Technologies (A) has a strong track record of exceeding analyst EPS expectations, with the most recent quarter (August 2026) showing an actual EPS of $1.62 against an estimate of $1.49, a positive surprise of 8.72%. This follows a pattern of positive surprises in prior quarters, with the exception of a minor miss in February 2026. The stock reacted positively to the latest earnings beat, gaining 1.68%. Revenue growth has been consistently positive, reinforcing the company's ability to grow its top line.
Key Risks
A primary risk for Agilent Technologies (A) is the current bearish technical momentum, with the RSI indicating oversold conditions and the stock trading below its 20-day EMA. Moderate insider selling, with $4.2 million in sales versus no purchases, also warrants attention, although the overall verdict is 'Moderate Sell Signal' rather than a strong bearish indicator. Additionally, potential shifts in healthcare spending or increased competition within the diagnostics and research market could impact future growth.
Technical Indicators
| RSI (14) | 32.83 |
|---|---|
| MACD | 1.49 |
| SMA 50 | 142.78 |
| SMA 200 | 131.61 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($142.78) above the 200-day SMA ($131.61), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.50
Moderate correlation
Nasdaq 100 (QQQ)
+0.42
Moderate correlation
Bitcoin (BTC)
+0.03
Weak correlation
Gold (XAU)
+0.04
Weak correlation
Check Custom Correlation
Calculating correlation...
A Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
🟢 LONG ENTRY (click to switch)
CONSERVATIVE
$141.86
2% below current price (Pullback entry)
Lower risk, wait for pullback
AGGRESSIVE
$144.75
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$137.60
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (32.8) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$148.95
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$156.04
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$163.13
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for A is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 9, 2026.Growth of $10,000
A $10,000 investment in A in September 2016 would be worth about $32,721 today, compared with about $35,913 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in A today could grow to about $25,568 by 2036 in the base case, with a bull case near $80,249 and a bear case around $8,146. Projections are statistical simulations, not guarantees.
A Stock Price Prediction: 2030
CleaRank's simulation projects a price near $211 for A by 2030 in the base case, from $145 today (1.5x over 4 years). The downside path ends near $102. These are outcomes of a Monte Carlo simulation run on A's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $111 | $159 | $228 |
| 2028 | $105 | $175 | $291 |
| 2029 | $103 | $192 | $359 |
| 2030 | $102 | $211 | $434 |
| 2031 | $103 | $231 | $520 |
| 2032 | $105 | $254 | $617 |
| 2033 | $107 | $279 | $727 |
| 2034 | $110 | $307 | $853 |
| 2035 | $114 | $337 | $997 |
| 2036 | $118 | $370 | $1,162 |
Method: 10,000 simulated price paths using A's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
A Insider Trading Analysis
Bought
None
No open-market buys
Sold
$4.2M
11 Transactions
Insiders
22
Active Traders
Avg Transaction
$379.5K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 22, 2022 | MCMULLEN MICHAEL R
Chief Executive Officer
|
Sell | 128.7K | $20.0M |
| Dec 20, 2021 | MCMULLEN MICHAEL R
Chief Executive Officer
|
Sell | 123.5K | $18.4M |
| Dec 1, 2020 | MCMULLEN MICHAEL R
Chief Executive Officer
|
Sell | 85.8K | $9.9M |
| Dec 7, 2023 | MCMULLEN MICHAEL R
Chief Executive Officer
|
Sell | 62.5K | $8.1M |
| Mar 8, 2024 | MCMULLEN MICHAEL R
Chief Executive Officer
|
Sell | 52.3K | $7.8M |
| Feb 2, 2021 | MCMULLEN MICHAEL R
Chief Executive Officer
|
Sell | 63.2K | $7.7M |
| Jul 30, 2020 | MCMULLEN MICHAEL R
Chief Executive Officer
|
Sell | 72.7K | $7.0M |
| Jun 14, 2021 | ANCHER JENSEN HENRIK
Officer
|
Sell | 43.7K | $6.3M |
| Dec 14, 2022 | ANCHER JENSEN HENRIK
Officer
|
Sell | 29.5K | $4.6M |
| Dec 10, 2019 | MCMULLEN MICHAEL R
Chief Executive Officer
|
Sell | 49.3K | $4.0M |
Page 1 of 1
Frequently Asked Questions
Is Agilent Technologies (A) stock a buy right now?
Agilent Technologies (A) is currently rated a 'Buy' by Wall Street analysts, with a median price target of $177.50, suggesting a 22.6% upside from its current price of $144.75. The company has a history of beating earnings estimates and shows consistent revenue growth.
What is Agilent Technologies' (A) long-term outlook?
The long-term outlook for Agilent Technologies (A) appears positive, with a projected 2030 base case price of $210.71 from Monte Carlo simulations. The company is expected to continue its revenue growth trajectory, supported by its strong position in the healthcare diagnostics and research sector.
What are the key growth drivers for Agilent Technologies (A)?
Key growth drivers for Agilent Technologies (A) include its consistent innovation in diagnostics and research, strong execution leading to regular earnings beats, and steady revenue growth projected at 8.1% for the current year. The company's ability to maintain analyst confidence also supports its growth prospects.
How has Agilent Technologies (A) performed in recent earnings reports?
Agilent Technologies (A) has consistently surpassed analyst EPS expectations in recent quarters. The latest report in August 2026 showed an 8.72% positive surprise, and the stock saw a 1.68% increase following the announcement, indicating positive market reception to its earnings performance.
What is the consensus rating for Agilent Technologies (A) stock?
The consensus rating for Agilent Technologies (A) stock among 22 Wall Street analysts is predominantly 'Buy'. The overall Wall Street score is 73 out of 100, reflecting strong analyst conviction in the company's prospects.
Are there any significant insider transactions for Agilent Technologies (A)?
Insider activity for Agilent Technologies (A) shows a 'Moderate Sell Signal', with $4.2 million in total sales and no reported purchases in recent filings. While this indicates a net selling trend among insiders, it does not represent a strong bearish signal.
What is the upside potential for Agilent Technologies (A) based on analyst targets?
Based on the median analyst price target of $177.50, Agilent Technologies (A) has an upside potential of 22.6% from its current trading price of $144.75.
What is Agilent Technologies' (A) stock price prediction for 2030?
A Monte Carlo simulation projects Agilent Technologies' (A) stock price to reach a base case of $210.71 by 2030, with a downside projection of $102.22 and an upside projection of $434.38. These are statistical outcomes, not guarantees.